MedTrace Logo

Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease

NCT02284932 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2016-09-08

No results posted yet for this study

Summary

Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality.

One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.

Conditions

Interventions

OTHER

No specific intervention for this study

No specific intervention for this study

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Laval University

    lead OTHER

Principal Investigators

  • François Maltais, MD, PhD · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2017-09-30
Completion
2018-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02284932 on ClinicalTrials.gov